& 2003 Nature Publishing Group All rights reserved /03 $
|
|
- Jack Hill
- 6 years ago
- Views:
Transcription
1 (2003) 31, & 2003 Nature Publishing Group All rights reserved /03 $ Progenitor cell mobilization : safety profile and variables affecting peripheral blood progenitor cell collection J Sevilla 1, M González-Vicent 1, L Madero 1, F García-Sánchez 2 and M Angel Díaz 1 1 Hospital Infantil Universitario Nin o Jesu s, Avd Mene ndez Pelayo 65, Madrid, Spain; and 2 Centro de Tranfusio n de la Comunidad de Madrid, Avd Mene ndez Pelayo 65, Madrid, Spain Summary: Large volume leukapheresis (LVL) has been proposed as a simplified single-apheresis approach to collect the target number of CD34 + cells. We retrospectively analyzed results of LVL in cytokine-mobilized patients weighing less than 20 kg to evaluate adverse events and variables affecting the yield. The only major adverse event recorded was transient and reversible systolic hypotension (three episodes). All the other adverse events were mild and did not require treatment. In multivariate analysis leukocyte count (P ¼ 0.001) and younger age (P ¼ 0.009) affected the CD34 + cell number in the peripheral blood before apheresis. The number of CD34 + cells before the apheresis was the only variable affecting CD34 + cell yield in multivariate analysis (P ¼ ). In all, 77% of patients achieved the target CD34 + cell dose of / kg in their first apheresis. Recruitment was seen in 72% of the procedures, and this was related to the total blood volume processed (P ¼ ). (2003) 31, doi: /sj.bmt Keywords: large-volume leukapheresis; LVL; apheresis; children; adverse events; recruitment In children, peripheral blood progenitor cells (PBPCs) have largely replaced bone marrow as source of autologous stem cells in part because of their relatively easy collection. However, there is a concern regarding medical, psychological, social and technical difficulties in small patients. 1 3 Large volume leukapheresis (LVL) defined as the processing of more than three volumes of blood in a single session 4 has been proposed as a simplified singleapheresis approach allowing us to obtain a CD34 + target cell dose with fewer apheresis procedures. We report a safety study on LVL in small patients. We have also analyzed the variables affecting PBPC collection by this procedure. Correspondence: Dr J Sevilla, Hospital Infantil Universitario Nin o Jesu s, Avd Mene ndez Pelayo 65, Madrid 28009, Spain Received 11 July 2002; accepted 11 September 2002 Patients and methods In all, 89 progenitor cell collections by LVL were performed in 66 consecutive patients (male 42, female 24) weighing less than 20 kg (median 15 kg; range 7 20) between December 1993and December 2001 for autologous transplantation. Median age was 40 months (10 79). In total, 46 patients had solid tumors including neuroblastoma (18), central nervous system tumor (18), rabdomyosarcoma (5), primitive neuroectodermal tumor (2), Wilm s tumor (2) and germinal tumor (1). In all, 19 had hematologic malignancies including acute myeloid leukemia (8), acute lymphoid leukemia (8) and non-hodgkin s lymphoma (3). One patient had a non-malignant disease (osteopetrosis). Patients underwent 78 mobilization courses with cytokines in different schedules. A total of 11 procedures were performed on the second or third day after the first apheresis day. Total blood volume (TBV) was estimated multiplying body weight by 80, as previously reported. 5,6 Parental consent was obtained in every patient. Mobilization Four different mobilization schedules were used over this period of time: G-CSF alone at a dose of 12 mg/kg/ day (n ¼ 53), or 10 mg/kg/day(n ¼ 1), or 12 mg/kg/12 h (n ¼ 26), or G-CSF+GM-CSF at a dose of 12 mg/kg/day of G-CSF and GM-CSF at a dose of 5 mg/kg/day(n ¼ 9), given subcutaneously for 4 5 days before starting PBCP apheresis. Vascular access LVL were performed via central venous catheter (Arrow- Howes, Reading, PA, USA) with offset lumens. Catheters were placed as previously reported, 7 but in this series mainly femoral access was elected. An attempt was made to use the same catheter for harvesting and transplantation. Peripheral blood progenitor cell (PBPC) collection LVL were performed in the Pediatric Oncology Department, in a quiet room where the patients stayed with their families. Patients were not routinely sedated. PBPC were collected by a COBE Spectra cell separator (COBE, Denver, CO, USA) as described elsewhere. 8 Leukapheresis
2 264 was performed on the 5th day of mobilization. A median of one (range 1 3) apheresis was performed per mobilization regimen. Prior treatment Each different course of chemotherapy the patient received before every apheresis was counted as a chemotherapy cycle. In total, 11 procedures were performed in patients that did not receive chemotherapy before the apheresis, 20 procedures in patients that had received up to 5 cycles of chemotherapy, and 58 procedures in patients who had received more than five cycles. In all, 66 apheresis were performed on patients who had not received previous radiotherapy treatment. In total, 20 apheresis were performed on patients who had prior radiotherapy treatment, and in three cases information regarding prior radiotherapy treatment was not available. Priming The cell separator was primed with a unit of irradiated and leukocyte-depleted packed red blood cells. Anticoagulant Initially acid citrate dextrose (ACD-A) was used as anticoagulant with the inlet : anticoagulant ratio being fixed automatically by the cell separator. Since June 1997, a solution of 500 ml ACD and 5000 IU of preservative-free heparin was infused at a whole blood to anticoagulant ratio of 30 : 1 for anticoagulation. Platelet clumping was prevented by adding heparin to the collection bag. Anticoagulation schedule was performed with ACD-A in 46 procedures, and with ACD-A and heparin in 43procedures. CD34+ cells determination Leukapheresis products and peripheral blood were analyzed for expression of the CD34 antigen as previously reported. 2,8 CD34 + cell quantification in peripheral blood was performed inmediately before the procedure. Efficiency and recruitment Collection efficiency (CE) was calculated according to Ford et al (10) formula, and the recruitment in each procedure according to Torrabadella et al. 5 To determine if there was recruitment of CD34 + cells during LVL in our series, we followed the procedure described by Cull et al. 11 Briefly, they calculated the absolute CD34 + cells in peripheral blood before apheresis and compared it with the total CD34 + cells collected in their series. Safety Adverse events related with mobilization were evaluated retrospectively until December Since January 2000, data related with mobilization were recorded prospectively. Adverse effects related with leukapheresis were evaluated retrospectively until December 1999, and prospectively since January These data were obtained following the Hemapheresis Committee of the American Association of Blood Banks questionnaire. 12 In our series, we have included some adverse events considered physiologic effects by these authors, as mild paresthesias, perioral tingling or mild vasovagal events. Changes in peripheral blood counts were also analyzed, and the influence of time or volume processed during LVL evaluated. Statistical analysis A software program (Statview 4.0, Abacus Concept, Berkeley, CA, USA) was used for statistical analysis. Correlations were determined using linear regression. The influence of variables that could affect the CD34 + cell count preapheresis and CD34+ cell yield was examinated by univariate and multivariate analysis using a stepwise regression model. Results were considered significant if the P value was o0.05. Results Safety Only three adverse events were recorded related with mobilization (low fever, headache and myalgia). Vasovagal events were the most frequent adverse events related with leukapheresis (Table 1). Mild decrease in blood pressure and diaphoresis was found in nine cases, seven of them with nausea. Three cases of systolic hypotension were recorded as severe adverse events during the procedure. These patients (with no special characteristics) rapidly responded to plasma volume expanders, and the procedure did not need to be interrupted. Three patients suffered pain or hematoma at the venipuncture site. Minor bleeding, not requiring treatment, after removal of central venous catheter was observed in three patients. Four patients on anticoagulation treatment only with ACD-A suffered perioral tingling although these patients usually had prophylactic treatment with calcium gluconate requiring additional calcium treatment. One patient also had nausea probably related with citrate toxicity. Treatment with calcium was necessary in all these patients. Table 1 Incidence of adverse events Adverse events Number Citrate effects Nausea and/or vomiting 1 Perioral tingling 4 Vasovagal effects Pallor and/or diaphoresis 9 Hypotension 9 Systolic blood pressure o80 3 Pulse > Venipuncture Pain 3 Palpable hematoma 1
3 There were significant changes in peripheral blood counts following each procedure. Median platelet loss was 52%, but platelet transfusion was not required in any patient. Platelet loss was related to the blood volumes processed (P ¼ ), but not to the time employed for the procedure. Even with red blood cells priming, there was difference between pre-lvl and post-lvl hematocrit (32% vs 29%; P ¼ ). There was also difference between pre-lvl and post-lvl leukocyte number/ml (34.5 vs 25.0; P ¼ ) Evaluation of leukapheresis parameters Total blood volume processed (median 5611 range ) and blood volumes processed (median 4.6 range 3 8.4) defined this series as LVL since more than three blood volumes were processed in all procedures. LVL results are described in Table 2. Of 34 patients mobilized in their first mobilization course with G-CSF at a dose of 12 mg/kg/day, 24 achieved the target dose in a single procedure (58.8%) and 10 patients required at least a second procedure. However, those patients mobilized with 12 mg/kg/12 h achieved the target dose by one leukapheresis in 95.2% of procedures (20 of 21 LVL). Finally, six of seven patients mobilized with G-CSF+GM-CSF achieved the target dose in their first leukapheresis (85%). Recruitment Recruitment was evaluated in 50 procedures since CD34 + cell count before the apheresis was available in these cases. Most of these procedures had recruitment in our series (72%) with a median of 1.2 (range ). According to Cull et al, 11 a mean absolute CD34 + cell count of was calculated before apheresis. The mean number of total CD34 + cells collected was (range ). Therefore, a mean of 1.17-fold greater CD34 + cells was collected than were present in peripheral blood before the procedure (P ¼ 0.04). The only variable affecting the recruitment was total blood volume processed (P ¼ ). Collection efficiency Median CE was 27.5 ( ). No variable affected CE (total blood volume processed, time, leukocyte count before the procedure, hematocrit or age). Variables affecting CD34 + cell number in peripheral blood before leukapheresis Median CD34 + cell/ml in peripheral blood before each apheresis was 59 (range 2 319) (n ¼ 50). There were several variables affecting CD34 + cell number before apheresis (Table 3). Higher platelet and leukocyte count before apheresis and younger age were related in the univariate 265 Table 2 Large volume leukapheresis results Characteristic Large volume leukapheresis procedures (n=88) Number of apheresis performed after each mobilization course Median 1 Range 1 3 Total blood volume Median 1200 Range Total blood volume processed (ml) Median 5611 Range Blood volume processed (ml/kg) Median 367 Range Blood volumes processed Median 4.6 Range Inlet/flow (ml/min) Median 20 Range 6 50 Time (min) Median 280 Range CD34+cells 10 6 /kg Median 5.5 Range Table 3 Variable Variables affecting CD34+ cell count preapheresis Median (range)- CD34+ cells/ml- Age (months) a Leukocytes preapheresis/ml a Platelets preapheresis/ml a Diagnosis group b Hematologic malignancy 32 (2 292) Solid neoplasia 80 (4 319) Diagnosis b Acute lymphoid leukemia 32 (2 84) Acute myeloid leukemia 93(29 292) Non-Hodgkin s lymphoma 33 (19 58) Neuroblastoma 36 (4 136) Wilm s tumor 62 (38 86) Germinal tumor 88 (61 115) Primitive neuroectodermal 146 (94 199) tumor Central nervous system 114 (26 319) tumor Rabdomyosarcoma 49 (30 154) Prior chemotherapy b None 94 (26 319) o 6 cycles 125 (29 292) X 6 cycles 40 (2 192) Radiotherapy c No 80 (7 292) Yes 12 (2 96) Mobilization schedule b G-CSF 12 mg/kg/day 40 (2 134) G-CSF 24 mg/kg/day 86 (4 319) GM-CSF+G-CSF 40 (5 94) a Analyzed by linear regression analysis. b Analyzed by Kruskal Wallis test. c Analyzed by Mann Whitney test. r 0.3; P=0.05 r 0.4; P=0.004 r 0.4; P=0.01 P=0.03 P=0.01 P=0.004 P=0.008 P=0.04
4 266 Table 4 Variable Variables affecting CD34+ cell yield Median (range)- CD34+ cells 10 6 /kg- Age (months) a Sex b Mobilization course b First 8.2 ( ) Second 3.9 ( ) Mobilization schedule c Leukocytes preapheresis/ml a Platelets preapheresis/ml a CD34+ cell preapheresis/ml a Diagnosis group c Hematologic malignancy 6 (0.2 35) Solid neoplasia 8 ( ) Diagnosis c Status c Prior chemotherapy c None 9.29 ( ) o6 cycles 7.6 (0.6 35) >6 cycles 5.5 ( ) Radiotherapy b No 5.8 ( ) Yes 2.6 ( ) a Analyzed by linear regression analysis. b Analyzed by Mann Whitney test. c Analyzed by Kruskal Wallis test. analysis with higher CD34 + cell values. CD34 + cell count before apheresis in patients with solid tumors was higher than in patients diagnosed with hematologic malignancies (80 vs 32) being the neuroblastoma patients those whose yield was lower between those diagnosed with solid tumors (Table 3). Mobilization schedule was also related with CD34 + cell count. Those patients mobilized with higher doses of G-CSF had higher values than those mobilized with lower doses (12 mg/kg/day) or the combination of G- CSF and GM-CSF (86 vs 40 vs 40, respectively). Finally, the previous treatment was related with CD34 + cell count. Median CD34 + cell count in patients with prior radiotherapy was 12 vs 80 in those patients who had not received prior radiotherapy. There were also differences between those patients who received more or less than six cycles of chemotherapy (median 125 vs 40, respectively). In the multivariate analysis the leukocyte count before apheresis (P ¼ 0.001) and younger age (P ¼ 0.009) are the only variables related with higher CD34 + cell values in peripheral blood. Variables affecting CD34 + cell yield r 0.8; P= P=0.04 P=0.02 P=0.01 Median CD34 + cell yield was /kg (range ). Several variables had an influence on the yield of CD34 + cells in the univariate studies (Table 4). Diagnosis influenced the CD34 + cell yield in those patients diagnosed with solid tumors having higher yield than those patients diagnosed with hematologic malignancies (median 8 vs cells/kg). Those patients who received chemotherapy or radiotherapy before harvesting yielded less CD34 + cells than those who were not treated (Table 4). In the multivariate analysis, all these variables were included and CD34 + cell preapheresis was the only variable related with CD34 + cell yield (P ¼ ). Discussion In this study LVL has been found to be a safe procedure with only three patients suffering transient and reversible hypotension. All the other events were mild and did not require treatment. No serious complications have been recorded related with the vascular access, and no procedure was interrupted as the result of any physical difficulty. These complications were similar to our previous experience, 2 and that previously published by others. 1,3 Hematologic toxicities such as platelet and hematocrit drop are recognized complications of leukapheresis. 3,5,13 Changes in peripheral blood counts following LVL were found in our series with a median platelet loss of 52% being the main hematological toxicity. This result is similar to previous LVL series. Kanold et al 3 reported a 37% platelet depletion, and Torrabadella et al 5 a 39%. In this latter study, the authors referred a median platelet loss of 29% in their standard leukapheresis group with no significant differences when comparing with the LVL patients. However, in our series, platelet loss was strongly related with the blood volumes processed. Nevertheless, no serious bleeding has been found in our patients in accordance with the literature. 3,5 Recruitment, defined as a higher number of CD34 + cells collected than estimated in peripheral blood immediately before the procedure, was found in our study. In our series, 72% of the procedures showed recruitment. The mean amount of harvested CD34 + cells was 1.17-fold higher compared with the number of circulation CD34 + cells in peripheral blood before apheresis. We could not find any clinical or demographic characteristic that could determine which patients might improve their yield by recruiting progenitor cells. We only found total blood volume processed affecting the recruitment, with higher recruitment in those procedures with more blood volume processed. It will lead us to process more blood volume in those patients with lower CD34 + cells preapheresis in order to increase the yield. Some authors have defined the recruitment as a time-dependent or blood-processed phenomenon, 14 but we consider it merely as a higher collection than expected by the CD34 + cell quantification in peripheral blood before the procedure by processing more blood volume than in a standard apheresis. Whether the collection is much lower or not, after a determinate time or blood volume processed, is controversial. Gorlin et al 15 reported a significant decrease in the CD34 + cells collected after the first hour of procedure in younger patients. However, Abe et al 16 found a continuous supply of CD34 + cells during the procedure, with no decrease in their number. Recently, Cassens et al 14 found a continuous decrease in the CD34 + cells collected after a maximum peak during the second processed blood volume. We did not study the CD34 + cell kinetics during the procedure, but the recruitment is highly correlated with the total blood volume processed, and not with the time employed in the apheresis. Therefore, processing more blood volume allows us to collect more CD34 + cells from the peripheral blood, than previously estimated to be in the patient. LVL has a similar CE in this study to that previously reported. 5,10 However, hematocrit and leukocyte count
5 before apheresis are not related with CE as previously reported by others. 10 Several variables influence the CD34 + cell count preapheresis in the univariate study (Table 3). There is still some controversy related with the best dose of cytokines used for mobilization. In our series, patients mobilized with higher doses of G-CSF needed only one apheresis to achieved the CD34 + target cell dose in 95.2% of patients vs 59% in those mobilized with lower doses. We found this variable to be related to the CD34 + cell count preapheresis (P ¼ 0.04), but not with the CD34 + cell yield. This discrepancy may be because of the fact that we processed more blood volume in those patients that had lower CD34 + cell count preapheresis trying to achieved the target dose. It could lead to similar CD34 + cell yield. Some other variables were related to the CD34 + cell count preapheresis and not with the yield, and the explanation may be again in the blood volumes processed. In the multivariate analysis the leukocyte count before apheresis and younger age are the only variables related in our series with higher CD34 + cell values in peripheral blood. Higher leukocyte counts, with higher CD34 + cell numbers, may reflect a better hematopoietic response to cytokines in younger bone marrows. Several variables also influence the CD34 + cell yield in the univariate study. Diagnosis group is related to CD34 + cell yield with hematologic malignancies collecting less CD34 + cells. It may reflect some marrow disturbance by the disease, or the treatment employed. However, in the multivariate study, CD34 + cell count preapheresis is the only variable related with the yield. It has been repeatedly reported as the main variable related to the yield. Other complications studied in this paper are those related with cytokine mobilization and vascular access. Cytokine mobilization has been found to be safe although some adverse events have been reported in the past: splenic rupture, atypical dermatological lesions, acute iritis and acute gouty arthritis. 17 In this series no serious adverse event was found related to mobilization. Regarding vascular access we found pain as the only variable related to vascular access insertion. In general, no special vascular access is necessary for leukapheresis. Either apheresis catheters 2 as cuffed indwelling catheters, 18 or a special arterial access 19 have been used for collection without significant complications. In conclusion, LVL is a safe and efficient procedure, also in very small patients. Several variables are related with the number of CD34 + cells collected, but the CD34 + cell count preapheresis is the main variable that predicts the yield. Processing larger amounts of blood volume might lead to increase in the yield by recruiting progenitor cells. References 1 Gorlin JB, Humphreys D, Kent P et al. Pediatric large volume PBPC collections from patients under 25 kg: a primer. J Clin Apheresis 1996; 11: Diaz MA, Alegre A, Benito A et al. PBPC collection by largevolume leukapheresis in low-weight children. J Hematother 1998; 7: Kanold J, Halle P, Berger M et al. Large-volume leukapheresis procedure for PBPC collection in children weighing 15 kg or less: efficacy and safety evaluation. Med Pediatr Oncol 1999; 32: Alegre A, Dı az MA, Madero L. Large-volume leukapheresis for peripheral blood stem cell collection in children: a simplified single-apheresis approach. Bone Marrow Transplant. 1996; 17: Torrabadella M, Olive T, Ortega JJ et al. Enhanced HPC recruitment in children using LVL and a new automated apheresis system. Transfusion 2000; 40: Jeter EK, Rogers RL. Pediatric apheresis. In: Apheresis: Principles and Practice, McLeod BC, Price TH, Drew MJ (eds). AABB Editorial Board: Maryland, 1997, pp Madero L, Ruano D, Villa M et al. Non-tunneled catheters in children undergoing bone marrow transplantation. Bone Marrow Transplant 1996; 17: Diaz MA, Garcia-Sa nchez F, Lillo R et al. Large-volume leukapheresis in pediatric patients: pre-apheresis peripheral blood CD34+ cell count predicts progenitor cell yield. Haematologica 1999; 84: Diaz MA, Villa M, Madero L. Analysis of engraftment kinetics in pediatric patients undergoing autologous PBPC transplantation. J Hematother 1998; 7: Ford CD, Pace N, Lehman C. Factors affecting the efficiency of collection of CD34-positive peripheral blood cells by a blood cell separator. Transfusion 1998; 38: Cull G, Ivey J, Chase P et al. Collection and recruitment of CD34+ cells during large-volume leukapheresis. J Hematother 1997; 6: Mc Leod BC, Price TH, Owen H et al. Frequency of immediate adverse effects associated with apheresis donation. Transfusion 1998; 38: Takaue Y, Kawano Y, Abe T et al. Collection and transplantation of peripheral blood stem cells in very small children weighing 20 kg or less. Blood 1995; 86: Cassens U, Momkvist PH, Zuehlsdorf M et al. Kinetics of standardized large volume leukpheresis (LVL) in patients do not show a recruitment phenomenon of peripheral blood progenitor cells (PBPC). Bone Marrow Transplant 2001; 28: Gorlin JB, Vamvakas EC, Cooke E et al. LVL in pediatric patients: processing more blood diminishes the apparent magnitude of intra-apheresis recruitment. Transfusion 1996; 36: Abe T, Makimoto A, Kawano Y et al. Intra-apheresis recruitment of blood progenitor cells in children. Transfusion 1998; 38: Gutierrez-Delgado F, Bensinger W. Safety of granulocyte colony-stimulating factor in normal donors. Curr Opin Hematol 2001; 8: Kletzel M, Longino R, Rademaker AW et al. Peripheral blood stem cell transplantation in young children: experience with harvesting, mobilization and engraftment. Pediatr Transplant 1998; 2: Watanabe T, Kawano Y, Watanabe A et al. Autologous and allogeneic transplantation with peripheral blood CD34 + cells: a pediatric experience. Haematologica 1999; 84:
& 2007 Nature Publishing Group All rights reserved /07 $
(7), 437 441 & 7 Nature Publishing Group All rights reserved 268-3369/7 $. www.nature.com/bmt ORIGINAL ARTICLE Patients mobilizing large numbers of CD34 þ cells ( super mobilizers ) have improved survival
More informationHigh-dose chemotherapy, followed by autologous
TRANSPLANTATION AND CELLULAR ENGINEERING A prospective randomized trial of two popular mononuclear cell collection sets for autologous peripheral blood stem cell collection in multiple myeloma_02350 100..119
More informationEdwin A. Burgstaler MT, HP (ASCP) Jeffrey L. Winters MD. ASFA 2017 Annual Meeting May 5, MFMER slide-1
Comparison of Hematopoietic Progenitor Cell (HPC) Collection Using the Spectra Optia Continuous Mononuculear Cell (CMNC) Collections with a 26:1 Anticoagulant Ratio Versus an Anticoagulant ing Technique
More informationKEY WORDS: Hematopoietic stem cell mobilization, Granulocyte colony-stimulating factor, Healthy donor, Apheresis
Factors Associated with Peripheral Blood Stem Cell Yield in Volunteer Donors Mobilized with Granulocyte Colony-Stimulating Factors: The Impact of Donor Characteristics and Procedural Settings Tso-Fu Wang,
More informationHematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte-macrophage colonystimulating factor (G-CSF).
Hematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte colony-stimulating factor(g-csf). Granulocyte-macrophage colonystimulating factor (G-CSF). Interleukin-11
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Leukine Page: 1 of 6 Last Review Date: November 30, 2018 Leukine Description Leukine (sargramostim)
More informationBMTCN REVIEW COURSE PRE-TRANSPLANT CARE
BMTCN REVIEW COURSE PRE-TRANSPLANT CARE Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to edit the Master Experts
More informationCarlos Bachier, Josh Potter, Grant Potter, Rominna Sugay, Paul Shaughnessy, Kawah Chan, Veronica Jude, Renee Madden, Charles F.
High White Blood Cell Concentration in the Peripheral Blood Stem Cell Product Can Induce Seizures during Infusion of Autologous Peripheral Blood Stem Cells Carlos Bachier, Josh Potter, Grant Potter, Rominna
More informationLeukopak 101: A Brief Review of Apheresis
White Paper September 2016 Leukopak 101: A Brief Review of Apheresis Lily C. Trajman, Ph.D. Introduction Apheresis refers to the process by which blood is removed from a patient and separated into its
More information2. Is therapy prescribed by, or in consultation with, a hematologist and/or oncologist?
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Colony Stimulating Factors (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationTRANSPARENCY COMMITTEE. The legally binding text is the original French version OPINION. 21 June 2006
TRANSPARENCY COMMITTEE The legally binding text is the original French version OPINION 21 June 2006 Granocyte 13 (13.4 million IU/1 ml), powder and solvent in prefilled syringe for solution for injection
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.08 Subject: Leukine Page: 1 of 5 Last Review Date: September 15, 2017 Leukine Description Leukine
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 7 Last Review Date: December 2, 2016 Granix Description Granix (tbo-filgrastim)
More informationRegulatory Challenges in Apheresis Global Perspectives - Cell Therapy
Regulatory Challenges in Apheresis Global Perspectives - Cell Therapy Joseph (Yossi ) Schwartz, MD, MPH Director, Transfusion Medicine & Cellular Therapy Columbia University Medical Center New York Presbyterian
More informationAlgorithms to predict CD34+ cell collection with the new generation of cell separator machines
Algorithms to predict CD34+ cell collection with the new generation of cell separator machines Dr Kenny Douglas SNBTS Clinical Apheresis Unit Beatson West of Scotland Cancer Centre Glasgow, U.K. Predicting
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Subject: Granix 1 of 7 Last Review Date: September 18, 2015 Granix Description Granix (tbo-filgrastim)
More informationWhite Cell Depletion for Leukocytosis
White Cell Depletion for Leukocytosis Objectives Discuss the indication for leukoreduction Identify IV access needs for patients receiving leukapheresis Outline ways to maintain fluid and electrolyte balance
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 16 December 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 16 December 2009 MOZOBIL 20 mg/ml, solution for injection Box containing 1 vial (CIP: 397 153-7) Applicant: GENZYME
More informationReview of New Platforms for Blood Prime
Review of New Platforms for Blood Prime Edwin A. Burgstaler, MT, HP(ASCP) ASFA 2015 Annual Meeting May, 2015 2015 MFMER slide-1 Objectives The participant will recognize the basic steps in performing a
More informationDepartment of Pharmacy, Georgia Health Sciences University, Augusta, GA, USA 3
Oncology Volume 2012, Article ID 931071, 5 pages doi:10.1155/2012/931071 Research Article Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Section: Prescription Drugs Effective Date: April 1, 2014 Subject: Granix 1 of 7 Last Review Date:
More informationSpanish Donor Registry. Follow-Up Data
Spanish Donor Registry. Follow-Up Data Javier de la Rubia S. de Hematología Hospital La Fe Valencia 16th Haemovigilance Seminar Barcelona, March 2014 WHO declared 2010 in its Guiding principle Nr.10: Hig-quality,
More informationIntroduction to Hematopoietic Stem Cell Transplantation
Faculty Disclosures Introduction to Hematopoietic Stem Cell Transplantation Nothing to disclose Jeanne McCarthy-Kaiser, PharmD, BCOP Clinical Pharmacist, Autologous Stem Cell Transplant/Long- Term Follow-Up
More informationSTEM CELL TRANSPLANT IN PEDIATRICS. Erin Meyer, DO, MPH Medical Director, Apheresis Nationwide Children s Hospital Columbus, OH 5/6/17
STEM CELL TRANSPLANT IN PEDIATRICS Erin Meyer, DO, MPH Medical Director, Apheresis Nationwide Children s Hospital Columbus, OH 5/6/17 Disclosures Nothing to Disclose Overview Stem Cell Transplant History
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 6 Last Review Date: September 15, 2017 Granix Description Granix (tbo-filgrastim)
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa
More informationBlood and Marrow Transplant (BMT) for Sickle Cell Disease
Blood and Marrow Transplant (BMT) for Sickle Cell Disease Rhiannon is now cured of sickle cell disease after BMT. Blood and marrow transplant (BMT) is a proven cure for sickle cell disease. This handbook
More informationDr.PSRK.Sastry MD, ECMO
Peripheral blood stem cell transplantation (Haematopoietic stem cell transplantation) Dr.PSRK.Sastry MD, ECMO Consultant, Medical Oncology Kokilaben Dhirubhai Ambani Hospital Normal hematopoiesis Historical
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization MERC CARE (MEDICAID) Colony Stimulating Factors (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationDonor work up, follow up and ethical issues
Donor work up, follow up and ethical issues Hans Hägglund MD. PhD. Associate Professor Hematology Center, Karolinska University Hospital, Stockholm, Sweden Outline The donor has been identified as a match
More informationClinical Applications: Donor and Cellular Therapy. Jay S. Raval, MD University of North Carolina Chapel Hill, NC
Clinical Applications: Donor and Cellular Therapy Jay S. Raval, MD University of North Carolina Chapel Hill, NC None Conflicts of Interest Objectives Donor Collections of Red Blood Cells (RBCs), Plasma,
More informationAutologous peripheral blood stem cells (PBSC)
998; 83-6 9-3-25 9:27 Pagina 489 Haematologica 998; 83:489-495 original paper C D 3 4 + cell dose and CD33 subsets: collection and engraftment kinetics in autologous peripheral blood stem cells tra n s
More informationImmature Reticulocyte Fraction in Guiding Stem Cell Harvest in Autologous Peripheral Blood Stem Cell Transplant
Malaysian Journal Immature of Medicine Reticulocyte and Health Fraction Sciences in (ISSN Guiding 1675-8544); Stem Cell Harvest Vol. 10 (1) in Autologous Jan 2014: 1-6 Peripheral Blood Stem Cell Transplant
More informationTherapeutic Leukocyte Reduction (TLR) For Myeloid Leukaemia's : A Four Year Experience From An Oncology Centre In India
Therapeutic Leukocyte Reduction (TLR) For Myeloid Leukaemia's : A Four Year Experience From An Oncology Centre In India Anita Tendulkar, Jain P, Gupta A, Sharma N, Navkudkar A, Patle V Dr Anita Tendulkar
More informationStony Brook University Hospital, Stony Brook, NY 2. TaiGen Biotechnology Co., Ltd, Taipei, Taiwan
A Phase 2, Open-label Study to Evaluate the Safety and Hematopoietic Stem Cell Mobilization of TG- 0054 (burixafor) Alone or in Combination with G- CSF in Patients with Multiple Myeloma, Non- Hodgkin s
More informationWelcome to esessions. Presented by CaridianBCT. PN CaridianBCT
Welcome to esessions Presented by CaridianBCT Presentation Overview Definition of TPE Rationale for TPE Role of TPE in the treatment of autoimmune diseases Procedural elements Definition of TPE Removal
More informationWAA/SFH Joint Congress
WAA/SFH Joint Congress Paris, 27 29 April 2016 Mobilization of HSC: History, evolution & impact Pitié-Sâlpétrière Hospital-Paris- France University Hospital of Paris-VI Nabih AZAR MD Key areas covered
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa
More informationClinical Policy: Donor Lymphocyte Infusion
Clinical Policy: Reference Number: PA.CP.MP.101 Effective Date: 01/18 Last Review Date: 11/16 Coding Implications Revision Log This policy describes the medical necessity requirements for a donor lymphocyte
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.08 Subject: Leukine Page: 1 of 6 Last Review Date: March 13, 2014 Leukine Description Leukine (sargramostim)
More information"Chemotherapy based stem cell mobilization: pro and con"
"Chemotherapy based stem cell mobilization: pro and con" Mohamad MOHTY Clinical Hematology and Cellular Therapy Dpt. Sorbonne Université Hôpital Saint Antoine Paris, France Disclosures Sponsorship or research
More informationAllogeneic Stem Cell Transplantation with Peripheral Blood Stem Cells Mobilized by Pegylated G-CSF
Biology of Blood and Marrow Transplantation 12:63-67 (26) 26 American Society for Blood and Marrow Transplantation 183-8791/6/126-2$32./ doi:1.116/j.bbmt.26.3.1 Allogeneic Stem Cell Transplantation with
More informationCitation for published version (APA): Hovenga, S. (2007). Clinical and biological aspects of Multiple Myeloma s.n.
University of Groningen Clinical and biological aspects of Multiple Myeloma Hovenga, Sjoerd IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More information2/4/14. Plerixafor. Learning Objective
Efficacy of late Hematopoietic Stem Cell Mobilization 35-40 hours after administration of Vikas Bhushan, MD Attending Physician, Stem Cell Transplantation, Medical City Hospital Dallas, TX Cyclam Rings
More informationHSCT MANAGEMENT WHITE PAPER. Managing stem cell apheresis effectively
HAEMATOLOGY JANUARY 2017 WHITE PAPER HSCT MANAGEMENT Managing stem cell apheresis effectively Haematopoietic stem cell transplantation Haematopoietic stem cell transplantation (HSCT) is a treatment that
More informationIMPACT OF A DATA-DRIVEN PREDICTION ALGORITHM FOR BLOOD VOLUME PROCESSING IN PERIPHERAL BLOOD STEM CELL COLLECTION IN UNRELATED (NMDP) HPC DONORS
IMPACT OF A DATA-DRIVEN PREDICTION ALGORITHM FOR BLOOD VOLUME PROCESSING IN PERIPHERAL BLOOD STEM CELL COLLECTION IN UNRELATED (NMDP) HPC DONORS Anand Padmanabhan, MD PhD QIA BloodCenter of Wisconsin Milwaukee,
More informationCyclophosphamide and paclitaxel as initial or salvage regimen for the mobilization of peripheral blood progenitor cells
Bone Marrow Transplantation, (1999) 24, 959 963 1999 Stockton Press All rights reserved 0268 3369/99 $15.00 http://www.stockton-press.co.uk/bmt Cyclophosphamide and paclitaxel as initial or salvage regimen
More informationSusan L. Pinkard, RN Manager, Therapeutic Apheresis Hoxworth Blood Center University Of Cincinnati Academic Health Center Cincinnati, Ohio
Susan L. Pinkard, RN Manager, Therapeutic Apheresis Hoxworth Blood Center University Of Cincinnati Academic Health Center Cincinnati, Ohio The Good: What indications we using to initiate photopheresis
More informationSponsor: Sanofi Drug substance(s): GZ316455
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MOZOBIL safely and effectively. See full prescribing information for MOZOBIL. MOZOBIL (plerixafor
More informationTransplantation - Challenges for the future. Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust
Transplantation - Challenges for the future Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust Bone Marrow Transplantation Timeline, 1957-2006 Appelbaum F. N Engl J Med 2007;357:1472-1475
More informationINFUSION OF HEMATOPOETIC STEM CELLS
INFUSION OF HEMATOPOETIC STEM CELLS BY KARLA BELL RN, CPHON PRESENTED BY JILLIAN CAREY, BSN, RN-BC, CPHON TYPES OF HEMATOPOIETIC CELLS Peripheral Blood Stem Cells (PBSC) Fresh or cryopreserved Cord Blood
More informationCorrelation of CD34 + Cell Yield in Peripheral Blood Progenitor Cell Product with the Pre-leukapheresis Cell Counts in Peripheral Blood
Original Article Correlation of CD34 + Cell Yield in Peripheral Blood Progenitor Cell Product with the Pre-leukapheresis Cell Counts in Peripheral Blood RB Sawant, SB Rajadhyaksha Abstract Introduction
More informationE Aurlien, H Holte, A Pharo, S Kvaløy, E Jakobsen, EB Smeland and G Kvalheim. Summary:
Bone Marrow Transplantation, (1998) 21, 873 878 1998 Stockton Press All rights reserved 268 3369/98 $12. http://www.stockton-press.co.uk/bmt Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide
More informationLenograstim-mobilized peripheral blood progenitor cells in volunteer donors: an open label randomized split dose escalating study
(2) 25, 371 376 2 Macmillan Publishers Ltd All rights reserved 268 3369/ $15. www.nature.com/bmt Lenograstim-mobilized peripheral blood progenitor cells in volunteer donors: an open label randomized split
More informationStem cell transplantation. Dr Mohammed Karodia NHLS & UP
Stem cell transplantation Dr Mohammed Karodia NHLS & UP The use of haemopoeitic stem cells from a donor harvested from peripheral blood or bone marrow, to repopulate recipient bone marrow. Allogeneic From
More informationBlood Components & Indications for Transfusion. Neda Kalhor
Blood Components & Indications for Transfusion Neda Kalhor Blood products Cellular Components: Red blood cells - Leukocyte-reduced RBCs - Washed RBCs - Irradiated RBCs Platelets - Random-donor platelets
More informationPeripheral blood stem cells Number of viable CD34 + cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation
(22) 29, 967 972 22 Nature Publishing Group All rights reserved 268 3369/2 $25. www.nature.com/bmt Peripheral blood stem cells Number of viable CD34 + cells reinfused predicts engraftment in autologous
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationTherapeutic apheresis (introduction) Orieji Illoh, MD November 21, 2006
Therapeutic apheresis (introduction) Orieji Illoh, MD November 21, 2006 Apheresis Removal of blood Separation into component parts One component is retained and remainder is returned History First tried
More informationNeupogen (Filgrastim)/Neulasta (Pegfilgrastim)
Policy Number Reimbursement Policy NEU12182013RP Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 12/18/2013 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This
More informationLCD for Sargramostim (GM-CSF, Leukine ) (L29275)
LCD for Sargramostim (GM-CSF, Leukine ) (L29275) Contractor Information Contractor Name First Coast Service Options, Inc. Contractor Number 09102 Contractor Type MAC - Part B LCD ID Number L29275 LCD Information
More information12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization
Table of Contents: PART I: Molecular and Cellular Basis of Hematology 1 Anatomy and Pathophysiology of the Gene 2 Genomic Approaches to Hematology 3 Regulation of Gene Expression, Transcription, Splicing,
More informationUnderstanding the role of ex vivo T cell depletion
Prevention of graftversus-host disease (GVHD) Understanding the role of ex vivo T cell depletion Information for patients undergoing allogeneic stem cell transplantation in AML and their families 2 This
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Sargramostim (Leukine) Reference Number: CP.PHAR.295 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important
More informationR-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin
: Rituximab, Gemcitabine, Dexamethasone &Cisplatin INDICATION Relapsed or refractory Hodgkin and non-hodgkin lymphoma. Omit Rituximab for patients with Hodgkin Lymphoma or high grade T cell non-hodgkin
More informationCase-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT
Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT Erin Meyer, DO, MPH Assistant Medical Director of Blood, Tissue, and Apheresis Services Children s Healthcare
More informationStem Cell Mobilization Protocols: Filgrastim vs. Mozobil
White Paper September 2016 Stem Cell Mobilization Protocols: Filgrastim vs. Mozobil Lily C. Trajman, Ph.D. Introduction Hematopoietic stem cells (HSCs) are primitive cells capable of both self renewal
More informationSterility Testing of Peripheral Blood Stem cell (PBSC) harvests in a Tertiary Oncology Setup
Sterility Testing of Peripheral Blood Stem cell (PBSC) harvests in a Tertiary Oncology Setup Bankar S 1, Tirlotkar A 1, Ojha S 1, Bhat V 2,Kannan S 3, Rajadhyaksha S 1 1. Department of Transfusion Medicine,
More informationA PRIMER ON APHERESIS MEDICINE
A PRIMER ON APHERESIS MEDICINE Nicole Aqui, M.D. Assistant Professor Division of Transfusion Medicine Department of Pathology and Laboratory Medicine University of Pennsylvania What is Apheresis? Apheresis
More informationPeripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors
Bone Marrow Transplantation, (1999) 24, 1065 1071 1999 Stockton Press All rights reserved 0268 3369/99 $15.00 http://www.stockton-press.co.uk/bmt Peripheral blood stem cell mobilization and apheresis:
More informationPeripheral blood stem cells Donating stimulated peripheral blood stem cells vs bone marrow: do donors experience the procedures differently?
(2001) 27, 917 923 2001 Nature Publishing Group All rights reserved 0268 3369/01 $15.00 www.nature.com/bmt Peripheral blood stem cells Donating stimulated peripheral blood stem cells vs bone marrow: do
More informationHematopoietic Stem Cell Therapy
Hematopoietic Stem Cell Therapy Grace Totoe, MBChB, SBB CME August 2012 Accra-Ghana Hematopoietic Stem Cells Cells capable of self renewal and differentiation into all blood cell lineages Objectives Historical
More informationDEPARTMENT OF CLINICAL HEMATOLOGY
DEPARTMENT OF CLINICAL HEMATOLOGY What is blood? Blood is the vital fluid of the body, which performs diverse functions from delivering oxygen to each and every cell of the body to fighting against infections
More informationFor peripheral blood stem cell (PBSC) mobilization prior to and during leukapheresis in cancer patients preparing to undergo bone marrow ablation
Last Review: 4/2010 NON-FORMULARY Clinical Guideline Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF), Neumega (oprelvekin; rh-il-11), Leukine (sargramostim; GM-CSF) Indications Neupogen
More informationHematopoietic stem cell mobilization and collection. Koen Theunissen Hematologie Jessa Ziekenhuis Hasselt Limburgs Oncologisch Centrum
Hematopoietic stem cell mobilization and collection Koen Theunissen Hematologie Jessa Ziekenhuis Hasselt Limburgs Oncologisch Centrum Transplants Transplant Activity in the U.S. 1980-2010 14,000 12,000
More informationUICC EML Review 2014
UICC EML Review 2014 Granulocyte Stimulating Agents (G- CSF) Supplemental Document Many antineoplastic agents are cytotoxic to the bone marrow and prevent the development of granulocytes necessary to fight
More informationHematopoietic Stem Cells
Hematopoietic Stem Cells, Stem Cell Processing, and Joseph (Yossi) Schwartz, M irector, Hemotherapy and Stem Cell Processing Facility E-mail: js2745@columbia.edu Hematopoietic Stem Cells Sustain hematopoiesis
More informationRESEARCH COMMUNICATION. Factors Affecting Engraftment Time in Autologous Peripheral Stem Cell Transplantation
Factors Affecting Engraftment Time in Autologous Peripheral Stem Cell Transplantation RESEARCH COMMUNICATION Factors Affecting Engraftment Time in Autologous Peripheral Stem Cell Transplantation H. Mehmet
More informationPersonalized medicine - cancer immunotherapy
Personalized medicine - cancer immunotherapy Özcan Met, PhD Senior Staff Scientist, Cell Therapy Director Center for Cancer Immune Therapy Department of Hematology Department of Oncology University Hospital
More informationACGME Program Requirements for Graduate Medical Education in Pediatric Hematology-Oncology
ACGME Program Requirements for Graduate Medical Education in Pediatric Hematology-Oncology ACGME approved: June 27, 2006; effective: July 1, 2007 ACGME approved focused revision: September 30, 2012; effective:
More informationMobilization & Pre-Transplant Conditioning Regimens
Transplant Process & Pre-Transplant Conditioning Regimens (auto patients only) 30 days before BMT (allo donors) 5 days before BMT Conditioning (auto AND allo patients) Transplant A technique used to increase
More informationPlerixafor: mechanism of action
Plerixafor and GCSF in patients with lymphoma and multiple myeloma previously failing mobilization with G- CSF +/- chemotherapy for autologous hematopoietic stem cell mobilization: The Austrian experience
More informationOlive J Sturtevant, MHP, MT(ASCP)SBB/SLS, CQA Director, Cellular Therapy Quality Assurance Dana Farber Cancer Institute
Adverse Events associated with Cell Therapy Products Olive J Sturtevant, MHP, MT(ASCP)SBB/SLS, CQA Director, Cellular Therapy Quality Assurance Dana Farber Cancer Institute 2 Objectives Review the types
More informationWhat is an Apheresis Donation?
What are Platelets? Platelets are colorless, irregularly shaped bodies found in blood. The primary role of platelets is to prevent bleeding in injured blood vessel walls by forming an aggregate at the
More informationPredictive factors for long-term engraftment of autologous blood stem cells
(2000) 26, 1299 1304 2000 Macmillan Publishers Ltd All rights reserved 0268 3369/00 $15.00 www.nature.com/bmt Predictive factors for long-term engraftment of autologous blood stem cells PR Duggan 1, D
More informationAutologous hematopoietic stem cell (HSC)
TRANSPLANTATION AND CELLULAR ENGINEERING Adverse events of cryopreserved hematopoietic stem cell infusions in adults: a single-center observational study Zaher K. Otrock, Diane S. Sempek, Sherry Carey,
More informationDonor and Patient Care. Leah L. Irwin, RN, MSN, CRNP Nurse Manager of Apheresis, Infusion and Donor Services Transfusion Medicine
Donor and Patient Care Leah L. Irwin, RN, MSN, CRNP Nurse Manager of Apheresis, Infusion and Donor Services Transfusion Medicine May 3, 2016 Donor and Patient Care Assessment and Monitoring Replacement
More informationOverview of Use of G-CSF in the Treatment of Acute Radiation Injury
Overview of Use of G-CSF in the Treatment of Acute Radiation Injury Applied Research Associates, Inc. Glen Reeves Distribution Statement A: Approved for public release; distribution is unlimited. This
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationEBMT Complications and Quality of Life Working Party Educational Course
EBMT Complications and Quality of Life Working Party Educational Course Organisers: R. Duarte, G. Basak 23-24 October 2014, Warsaw, Poland #EBMT2014 www.ebmt.org EBMT Complications and Quality of Life
More information& 2005 Nature Publishing Group All rights reserved /05 $
(25), 183 188 & 25 Nature Publishing Group All rights reserved 28-39/5 $ www.nature.com/bmt Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic
More informationTable S1. World Health Organization bleeding scale
Table S1. World Health Organization bleeding scale Oral and nasal Skin, soft tissue, musculoskeletal Gastrointestinal Genitourinary Grade 1 Oropharyngeal bleeding total duration of all episodes in previous
More informationDepartment of Internal Medicine V, University of Heidelberg, Heidelberg, Germany;
Stem Cells Original Article Kinetics of Peripheral Blood Stem Cell Mobilization Following G-CSF-Supported Chemotherapy RUTH SEGGEWISS, a EIKE CHRISTIAN BUSS, a DORIS HERRMANN, b HARTMUT GOLDSCHMIDT, a
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationDonatore HLA identico di anni o MUD giovane?
Donatore HLA identico di 60-70 anni o MUD giovane? Stella Santarone Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie Pescara AGENDA 1. Stem Cell Donation: fatalities and severe events
More informationCopyright information:
A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous
More informationAngelo Ostuni. Servizio di Immunoematologia e Medicina Trasfusionale Azienda Ospedaliera Card. Panico Tricase (LE)
Impiego di cellule staminali autologhe da sangue periferico mobilizzate con Plerixafor nel trapianto di pazienti affetti da linfoma e mieloma multiplo. Angelo Ostuni Servizio di Immunoematologia e Medicina
More informationBone Marrow Transplantation and the Potential Role of Iomab-B
Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation
More informationNicole Laferriere MD PhD FRCPC April 10, Patient Case Studies: Sticky Situations For Platelet Transfusions
Nicole Laferriere MD PhD FRCPC April 10, 2019 Patient Case Studies: Sticky Situations For Platelet Transfusions Disclosures Ad Board: Celgene, Jansen, Takeda, Roche, Sanofi, Leo, Shire, Servier, Phizer,
More information